Drug intelligence / Profile preview

HR091506 + placebo

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HR091506 + placebo refers to a combination used in clinical trials where participants receive either the investigational drug HR091506 or a matching placebo. HR091506 is an oral small molecule under development by Jiangsu Hengrui Medicine for the treatment of gout and hyperuricemia in adults. Its precise mechanism of action has not been disclosed publicly, but it is being evaluated for its efficacy and safety compared to standard treatments such as febuxostat. The combination "HR091506 + placebo" specifically denotes the randomized controlled trial design rather than a fixed-dose pharmaceutical product.

Beyond the preview

Go deeper on HR091506 + placebo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HR091506 + placebo.

Explore the full profile